@prefix this: <http://purl.org/np/RASJaMbKa-cU8ftUssfy-9ujTrcHUr2ARWXqKWqyl3_pw> .
@prefix sub: <http://purl.org/np/RASJaMbKa-cU8ftUssfy-9ujTrcHUr2ARWXqKWqyl3_pw#> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix nt: <https://w3id.org/np/o/ntemplate/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix bl: <https://w3id.org/biolink/vocab/> .
@prefix nkg: <https://w3id.org/um/neurodkg/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  <http://purl.obolibrary.org/obo/MONDO_0004985> bl:category bl:Disease .
  
  sub:association rdf:object <http://purl.obolibrary.org/obo/MONDO_0004985>;
    rdf:predicate bl:treats;
    rdf:subject <https://go.drugbank.com/drugs/DB01221>;
    a rdf:Statement;
    rdfs:label "The most commonly reported diagnosis treated was Major Depressive Disorder (72.2%), followed by Bipolar Disorder (15.1%), and Posttraumatic Stress Disorder (5.7%). Most providers (87.7%) reported administering ketamine via an intravenous route, with a minority reporting using an oral (22.8%) or an intranasal (19.3%) formulation.";
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
    bl:has_population_context sub:cohort;
    bl:provided_by <https://w3id.org/um/NeuroDKG>;
    bl:publications <https://pubmed.ncbi.nlm.nih.gov/28669202/>;
    bl:relation nkg:OffLabelIndication .
  
  sub:cohort rdfs:label "Adults";
    bl:category bl:Cohort .
  
  <https://go.drugbank.com/drugs/DB01221> bl:category bl:Drug .
}

sub:provenance {
  sub:assertion prov:wasAttributedTo orcid:0000-0002-7641-6446 .
}

sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB";
    npx:hasSignature "a+SdXYUrjVz/3ANtCRCiba5OLdfnIUAxEknfVaHCqdVph5YgYGqZwuBoVK1CWM0bmi3v2i7rSbgm5yXF+m+BLYfG+TrXxy2cCDHkr3lqvh2y81HsUlml6Qz9ljfnaAWa1pwSF94CveX7egAgQa0vhXx/XgxOBUBKglLZU4peWJM=";
    npx:hasSignatureTarget this: .
  
  this: dct:created "2021-05-25T14:46:33.571+02:00"^^xsd:dateTime;
    dct:creator orcid:0000-0002-7641-6446;
    nt:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM>;
    nt:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM>;
    nt:wasCreatedFromTemplate <http://purl.org/np/RAZdZj78B6nKrP1Q00oFzsK07u7WdiY3sToz-H-H2nSgg> .
}